Loading…

Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)

NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This Policy Review elucidates some of the many cha...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2024-10, Vol.25 (10), p.e489-e500
Main Authors: Zumsteg, Zachary S, Sheth, Siddharth, Jabbour, Salma K, Patel, Krishnan R, Kimple, Randall J, Williams, Terence M, Xu-Welliver, Meng, Torres-Saavedra, Pedro A, Monjazeb, Arta M, Mayadev, Jyoti, Finkelstein, Steven E, Buatti, John M, Patel, Sandip P, Lin, Steven H
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This Policy Review elucidates some of the many challenges associated with study design for early phase trials combining radiotherapy with novel systemic agents, which are distinct from drug–drug combination development and are often overlooked. We also advocate for potential solutions that could mitigate or eliminate some of these barriers, providing examples of specific clinical trial designs that could help facilitate efficient and effective evaluation of novel drug–radiotherapy combinations.
ISSN:1470-2045
1474-5488
1474-5488
DOI:10.1016/S1470-2045(24)00264-X